Boston Scientific (BSX) Stock Price

Boston Scientific Price

NYSE·CLOSED
48.10USD+1.37 (+2.88 %)
Market closed

Revenue has compounded at 5.1% per year over the past 19 years to 20.07 B USD. Earnings per share have grown at 14.1% per year over the last 14 years. Boston Scientific's net margin stands at 14.4%, up from 8.7% several years earlier. Analysts set a median price target of 126.99 USD, implying 164.0% above the current price. Of 40 analysts, 37 rate the stock a buy — an overall Buy consensus. The stock trades about 13% above its 52-week low.

Boston Scientific stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Boston Scientific over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Boston Scientific stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Boston Scientific's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Boston Scientific Stock Price History
DateBoston Scientific Price
8/3/202648.10 USD
7/31/202646.73 USD
7/30/202646.00 USD
7/29/202646.25 USD
7/27/202646.15 USD
7/23/202643.58 USD
7/22/202642.97 USD
7/21/202643.19 USD
7/20/202643.77 USD
7/17/202644.03 USD
7/16/202644.62 USD
7/15/202643.04 USD
7/14/202642.63 USD
7/13/202644.80 USD
7/10/202644.77 USD
7/9/202644.99 USD
7/8/202644.70 USD
7/7/202645.30 USD
7/6/202644.20 USD
7/2/202645.14 USD
7/1/202643.06 USD
6/30/202642.68 USD
6/29/202643.85 USD
6/26/202644.23 USD
6/25/202644.20 USD
6/24/202644.46 USD
6/23/202645.60 USD
6/22/202644.25 USD
6/18/202645.47 USD
6/17/202646.19 USD
6/16/202646.66 USD
6/15/202647.03 USD
6/12/202646.51 USD
6/11/202646.96 USD
6/10/202648.42 USD
6/9/202648.96 USD
6/8/202648.70 USD
6/5/202649.61 USD
6/4/202648.42 USD
6/3/202647.70 USD
6/2/202647.92 USD
6/1/202647.72 USD
5/29/202648.92 USD
5/28/202649.09 USD
5/27/202651.69 USD
5/26/202657.85 USD
5/22/202657.49 USD
5/21/202656.82 USD
5/20/202656.63 USD
5/19/202656.81 USD
5/18/202655.92 USD
5/15/202652.68 USD
5/14/202653.55 USD
5/13/202653.06 USD
5/12/202654.10 USD
5/11/202653.37 USD
5/8/202653.93 USD
5/7/202656.57 USD
5/6/202656.00 USD
5/5/202655.98 USD
5/4/202656.85 USD
5/1/202656.50 USD
4/30/202657.61 USD
4/29/202657.15 USD
4/28/202658.45 USD
4/27/202659.95 USD
4/24/202662.07 USD
4/23/202665.69 USD
4/22/202664.87 USD
4/21/202659.52 USD
4/20/202660.99 USD
4/17/202664.23 USD
4/16/202663.42 USD
4/15/202664.61 USD
4/14/202663.82 USD
4/13/202663.18 USD
4/10/202661.79 USD
4/9/202661.28 USD
4/8/202662.56 USD
4/7/202661.86 USD
4/6/202662.59 USD
4/2/202662.82 USD
4/1/202662.00 USD
3/31/202662.75 USD
3/30/202662.93 USD
3/27/202669.17 USD
3/26/202670.17 USD
3/25/202669.78 USD
3/24/202668.15 USD
3/23/202669.54 USD
3/20/202669.48 USD
3/19/202669.89 USD
3/18/202671.28 USD
3/17/202671.20 USD
3/16/202669.79 USD
3/13/202669.13 USD
3/12/202668.55 USD
3/11/202669.63 USD
3/10/202669.96 USD
3/9/202671.90 USD
3/6/202671.35 USD
3/5/202672.99 USD
3/4/202672.21 USD
3/3/202673.85 USD
3/2/202676.22 USD
2/27/202676.85 USD
2/26/202675.75 USD
2/25/202673.48 USD
2/24/202675.15 USD
2/23/202674.37 USD
2/20/202674.58 USD
2/19/202675.72 USD
2/18/202676.28 USD
2/17/202676.29 USD
2/13/202674.73 USD
2/12/202674.12 USD
2/11/202673.47 USD
2/10/202674.25 USD
2/9/202674.12 USD
2/6/202676.27 USD
2/5/202677.64 USD
2/4/202675.50 USD
2/3/202691.62 USD
2/2/202691.87 USD
1/30/202693.53 USD
1/29/202692.33 USD
1/28/202693.79 USD
1/27/202693.61 USD
1/26/202693.55 USD
1/23/202692.51 USD
1/22/202691.29 USD
1/21/202691.71 USD
1/20/202691.20 USD
1/16/202688.07 USD
1/15/202690.03 USD
1/14/202693.74 USD
1/13/202694.14 USD
1/12/202695.72 USD
1/9/202697.64 USD
1/8/202698.38 USD
1/7/202698.65 USD
1/6/202697.79 USD
1/5/202695.48 USD
1/2/202694.71 USD
12/31/202595.35 USD
12/30/202596.01 USD
12/29/202595.76 USD
12/26/202596.06 USD
12/24/202596.13 USD
12/23/202596.09 USD
12/22/202596.43 USD
12/19/202595.61 USD
12/18/202596.11 USD
12/17/202594.48 USD
12/16/202592.95 USD
12/15/202592.19 USD
12/12/202592.58 USD
12/11/202591.75 USD
12/10/202592.70 USD
12/9/202592.53 USD
12/8/202593.84 USD
12/5/202597.52 USD
12/4/202597.72 USD
12/3/202598.57 USD
12/2/202599.02 USD
12/1/2025101.01 USD
11/28/2025101.58 USD
11/26/2025100.96 USD
11/25/2025101.36 USD
11/24/202598.04 USD
11/21/202596.88 USD
11/20/202596.60 USD
11/19/202597.01 USD
11/18/202599.22 USD
11/17/2025101.76 USD
11/14/2025102.69 USD
11/13/2025104.98 USD
11/12/2025104.13 USD
11/11/2025102.50 USD
11/10/2025100.91 USD
11/7/2025100.02 USD
11/6/202599.05 USD
11/5/202598.90 USD
11/4/202598.84 USD
11/3/202598.59 USD
10/31/2025100.72 USD
10/30/2025100.57 USD
10/29/2025100.30 USD
10/28/2025100.97 USD
10/27/2025102.43 USD
10/24/2025101.11 USD
10/23/2025102.39 USD
10/22/2025103.85 USD
10/21/202599.90 USD
10/20/2025100.53 USD
10/17/202599.24 USD
10/16/202597.78 USD
10/15/202597.71 USD
10/14/202596.24 USD
10/13/202594.95 USD
10/10/202595.41 USD
10/9/202597.28 USD
10/8/202596.79 USD
10/7/202595.90 USD
10/6/202596.70 USD
10/3/202597.32 USD
10/2/202596.22 USD
10/1/202595.85 USD
9/30/202597.63 USD
9/29/202597.04 USD
9/26/202598.18 USD
9/25/202598.14 USD
9/24/202598.06 USD
9/23/202597.69 USD
9/22/202597.03 USD
9/19/202597.83 USD
9/18/202598.23 USD
9/17/202598.50 USD
9/16/202598.98 USD
9/15/202599.87 USD
9/12/2025102.71 USD
9/11/2025104.34 USD
9/10/2025105.23 USD
9/9/2025108.09 USD
9/8/2025108.14 USD
9/5/2025107.22 USD
9/4/2025107.29 USD
9/3/2025107.53 USD
9/2/2025106.66 USD
8/29/2025105.50 USD
8/28/2025105.75 USD
8/27/2025105.87 USD
8/26/2025106.39 USD
8/25/2025105.11 USD
8/22/2025106.17 USD
8/21/2025105.21 USD
8/20/2025106.05 USD
8/19/2025103.75 USD
8/18/2025103.05 USD
8/15/2025103.17 USD
8/14/2025104.15 USD
8/13/2025102.50 USD
8/12/2025102.64 USD
8/11/2025102.75 USD
8/8/2025103.14 USD
8/7/2025102.96 USD
8/6/2025102.95 USD
8/5/2025104.83 USD
8/4/2025106.79 USD
Access this data via the Eulerpool API
Get Free API Key

Boston Scientific Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
14.24 B USD
2.18 B USD
1.59 B USD
Jan 1, 2024
16.75 B USD
2.64 B USD
1.85 B USD
Jan 1, 2025
20.07 B USD
3.97 B USD
2.89 B USD
Jan 1, 2026 (e)
21.60 B USD
3.24 B USD
4.98 B USD
Jan 1, 2027 (e)
23.27 B USD
3.49 B USD
5.49 B USD
Jan 1, 2028 (e)
25.12 B USD
3.77 B USD
6.11 B USD
Jan 1, 2029 (e)
27.77 B USD
4.17 B USD
6.92 B USD
Jan 1, 2030 (e)
30.59 B USD
4.59 B USD
7.70 B USD

Boston Scientific Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 9:10 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESB
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
7.488.399.059.8210.749.9111.8912.6814.2416.7520.0721.6023.2725.1227.7730.59
1.3112.167.898.579.28-7.6619.926.6812.2917.6119.877.597.757.9510.5310.17
61.0463.7164.8965.9464.0856.2562.7660.8362.0261.3169.0169.0169.0169.0169.0169.01
4.565.345.876.486.885.587.467.718.8310.2713.8514.9016.0617.3419.1621.11
0.790.411.161.741.130.601.921.822.182.643.973.243.493.774.174.59
10.574.9012.8517.6810.536.0616.1714.3815.3215.7319.7815.0115.0115.0015.0015.00
-0.240.350.101.674.70-0.081.040.701.591.852.894.985.496.116.927.70
100.84-245.19-70.031,506.73181.27-101.74-1,368.29-32.88128.2216.3855.6672.4510.2311.2813.3311.35
1.351.381.371.411.411.441.441.441.481.491.501.501.501.501.501.50
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Boston Scientific generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Boston Scientific retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Boston Scientific's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Boston Scientific has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Boston Scientific's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Boston Scientific stock margins

The Boston Scientific margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Boston Scientific. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Boston Scientific.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
62.76 %
16.17 %
8.75 %
Jan 1, 2022
60.83 %
14.38 %
5.50 %
Jan 1, 2023
62.02 %
15.32 %
11.19 %
Jan 1, 2024
61.31 %
15.73 %
11.07 %
Jan 1, 2025
69.01 %
19.78 %
14.38 %
Jan 1, 2026 (e)
69.01 %
15.01 %
23.05 %
Jan 1, 2027 (e)
69.01 %
15.01 %
23.58 %
Jan 1, 2028 (e)
69.01 %
15.01 %
24.30 %

Boston Scientific Stock Revenue, EBIT, Earnings per Share

The Boston Scientific earnings per share therefore indicates how much revenue Boston Scientific has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
8.28 USD
1.34 USD
0.72 USD
Jan 1, 2022
8.79 USD
1.26 USD
0.48 USD
Jan 1, 2023
9.64 USD
1.48 USD
1.08 USD
Jan 1, 2024
11.24 USD
1.77 USD
1.24 USD
Jan 1, 2025
13.42 USD
2.65 USD
1.93 USD
Jan 1, 2026 (e)
14.56 USD
2.17 USD
3.36 USD
Jan 1, 2027 (e)
15.69 USD
2.33 USD
3.70 USD
Jan 1, 2028 (e)
16.94 USD
2.52 USD
4.12 USD

Boston Scientific business model & stock analysis

Boston Scientific Corp. is a global medical technology company specializing in the development and manufacturing of innovative solutions for medical challenges and needs. The company was founded in 1979 and has since been dedicated to meeting the individual needs of patients and medical professionals with innovative products. The history of Boston Scientific began in the 1960s when French engineer Jean-Marc Simon started developing pacemakers at the University of Minnesota. In 1969, Medtronic acquired Simon's pacemaker development, leading to the founding of Boston Scientific. From the beginning, the company focused on the production of cardiovascular implants, including pacemakers, implanted defibrillators, and stents. In the following years, the company achieved continued growth through acquisitions of competitors and advancements in research and development, particularly in the field of minimally invasive procedures. Today, Boston Scientific is a globally leading provider of innovative medical devices and solutions used in various areas of healthcare. Boston Scientific's business model is based on meeting the needs of patients, medical professionals, and healthcare policymakers in order to improve healthcare. The company works closely with doctors, hospitals, nursing facilities, and research institutions to continuously develop innovative solutions for various diseases and conditions. Boston Scientific has five business segments: Cardiovascular Systems, Interventional Oncology and Neuromodulation, Urology and Women's Health, Medical Oncology, and Endoscopy. The Cardiovascular Systems segment includes products and solutions for cardiovascular surgery, including pacemakers, implanted defibrillators, and catheters. The company is also involved in endovascular surgery, offering innovative stent and catheter systems for the treatment of aneurysms and arterial occlusive disease. The Interventional Oncology and Neuromodulation segment includes solutions for the minimally invasive treatment of cancer and chronic pain through catheter and implant systems. For example, Boston Scientific offers intensity-controlled radiofrequency ablation and neuromodulation procedures. The Urology and Women's Health segment includes products for the treatment and diagnosis of urogenital system disorders, including incontinence, urinary incontinence, and genital diseases. Boston Scientific offers innovative solutions for women, such as the treatment of urinary incontinence or the removal of uterine fibroids. The Medical Oncology segment includes products for the diagnosis and treatment of cancer, including in vitro diagnostics and novel treatments such as chemotherapy delivery technology. The Endoscopy segment includes endoscopic solutions, including the diagnosis and therapy of digestive tract, chest, and lung disorders. Boston Scientific's product portfolio is diverse and includes numerous innovative medical devices and systems designed to meet the needs of patients and medical professionals. Some of the notable products of the company include: - The Implantable Cardioverter-Defibrillator (ICD) is an innovative device that can treat heart rhythm disorders through the use of a remote control. - Drug-Eluting Stents are stents that deliver medication directly at the site of narrowing, promoting blood flow and helping to keep the artery open. - The Synergy is a top-of-the-line stent that has both a lower mortality rate and a higher success rate than conventional stents. - The Venus-EP Steerable Sheath is an advanced catheter that allows physicians unique navigation within the heart chambers. - The Precision is a catheter that sends impulses to the heart for the diagnosis and treatment of atrial fibrillation. - The Transcend is a pacemaker that combines traditional pacemaker function with a sensor that actively supports the patient during physical activity. - The Symphion is an innovative system for laparoscopic surgery that enables minimally invasive surgical procedures in women. In conclusion, Boston Scientific Corp. is a globally leading provider of innovative medical devices and solutions that run like a common thread through its various business segments. With a significant focus on research and development, the company offers a wide range of products to ensure that patients worldwide have access to innovative medical care. Through pioneering innovations, the development of new technologies, and collaboration with medical professionals, Boston Scientific will continue to defend its position as a leading provider of medical solutions worldwide.

Boston Scientific SWOT Analysis

Strengths

Boston Scientific Corp has a strong portfolio of innovative medical devices and technologies that cater to a wide range of medical specialties.

The company has a global presence and operates in over 130 countries, providing access to a large customer base and potential for market expansion.

Boston Scientific Corp has a solid reputation for delivering high-quality products and services, leading to strong customer loyalty and trust.

Weaknesses

One of the weaknesses for Boston Scientific Corp is its dependence on third-party suppliers for certain critical components, which makes the company vulnerable to supply chain disruptions.

The company has faced challenges related to regulatory compliance, which can impact its ability to introduce new products and comply with changing market requirements.

Boston Scientific Corp operates in a highly competitive market, which puts pressure on pricing and profit margins.

Opportunities

The growing global healthcare market presents opportunities for Boston Scientific Corp to expand its customer base and increase sales.

Advancements in medical technology and increased adoption of minimally invasive procedures create opportunities for the company to develop and introduce new innovative products.

Expansion into emerging markets, such as Asia and Latin America, offers the potential for significant revenue growth for Boston Scientific Corp.

Threats

Intense competition from other medical device companies poses a threat to Boston Scientific Corp's market share and profitability.

Changes in healthcare regulations and policies can impact the pricing and reimbursement of medical devices, posing challenges to the company's financial performance.

Fluctuating currency exchange rates can affect Boston Scientific Corp's international operations and profitability.

Boston Scientific Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Boston Scientific Employees
Details
Date
Boston Scientific Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Boston Scientific Segments

Boston Scientific Revenue by Segment (1/6)

  • 3 Years

  • 5 Years

  • Max

Global Cardiology Reporting Unit
Global Interventional Cardiology (IC) Reporting Unit
Interventional Cardiology Therapies
Global Endoscopy (Endo) Reporting Unit
Cardiac Rhythm Management
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Watchman
Global Neuromodulation (NM) Reporting Unit
Electrophysiology (EP)
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
BTG Spec Pharma
Details
Date
Global Cardiology Reporting Unit
Global Interventional Cardiology (IC) Reporting Unit
Interventional Cardiology Therapies
Global Endoscopy (Endo) Reporting Unit
Cardiac Rhythm Management
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Watchman
Global Neuromodulation (NM) Reporting Unit
Electrophysiology (EP)
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
BTG Spec Pharma
Other
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
2.82 B USD
0.00 USD
1.89 B USD
0.00 USD
1.94 B USD
1.39 B USD
1.41 B USD
0.00 USD
873.00 M USD
0.00 USD
329.00 M USD
0.00 USD
11.00 M USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
13.00 M USD
0.00 USD
0.00 USD
Jan 1, 2022
5.93 B USD
0.00 USD
2.23 B USD
2.22 B USD
2.10 B USD
0.00 USD
1.90 B USD
1.77 B USD
1.02 B USD
917.00 M USD
585.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Boston Scientific Revenue by Segment (2/6)

  • 3 Years

  • Max

Other
Details
Date
Other
Jan 1, 2010
0.00 USD
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
-60.00 M USD

Boston Scientific Revenue by Segment (3/6)

  • 3 Years

  • 5 Years

  • Max

Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
Details
Date
Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Global CRM Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology and Pelvic Health Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Specialty Pharmaceuticals
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
2.30 B USD
1.78 B USD
1.70 B USD
1.58 B USD
1.29 B USD
761.00 M USD
287.00 M USD
219.00 M USD
Jan 1, 2021
3.04 B USD
2.14 B USD
2.02 B USD
1.82 B USD
1.58 B USD
909.00 M USD
365.00 M USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Boston Scientific Revenue by Segment (4/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

BSX Reportable Segments
Cardiovascular
MedSurg
Rhythm and Neuro
Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Global Peripheral Interventions (PI) Reporting Unit
Global Urology (Uro) Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Details
Date
BSX Reportable Segments
Cardiovascular
MedSurg
Rhythm and Neuro
Global Interventional Cardiology (IC) Reporting Unit
Global Endoscopy (Endo) Reporting Unit
Cardiac Rhythm Management
Global Peripheral Interventions (PI) Reporting Unit
Endoscopy
Global Urology (Uro) Reporting Unit
Global Neuromodulation (NM) Reporting Unit
Urology Women's/Health
Neurovascular
Neuromodulation
Electrophysiology
Jan 1, 2010
0.00 USD
3.27 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.18 B USD
0.00 USD
1.08 B USD
0.00 USD
0.00 USD
481.00 M USD
340.00 M USD
304.00 M USD
147.00 M USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.09 B USD
1.34 B USD
0.00 USD
861.00 M USD
0.00 USD
542.00 M USD
474.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.24 B USD
1.42 B USD
0.00 USD
975.00 M USD
0.00 USD
735.00 M USD
512.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
2.52 B USD
1.57 B USD
0.00 USD
1.09 B USD
0.00 USD
1.07 B USD
574.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
10.65 B USD
0.00 USD
3.31 B USD
3.14 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
3.88 B USD
3.07 B USD
2.75 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
4.86 B USD
3.72 B USD
3.29 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Boston Scientific Revenue by Segment (5/6)

  • 3 Years

  • 5 Years

  • Max

BSX Reportable Segments
Cardiovascular
MedSurg
Details
Date
BSX Reportable Segments
Cardiovascular
MedSurg
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
9.69 B USD
0.00 USD
0.00 USD
Jan 1, 2021
11.88 B USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
7.83 B USD
4.91 B USD

Boston Scientific Revenue by Segment (6/6)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Cardiovascular
MedSurg
Rhythm Management
Global CRM Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Other Segments
Details
Date
Cardiovascular
MedSurg
Rhythm Management
Global CRM Reporting Unit
Global Electrophysiology (EP) Reporting Unit
Other Segments
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2014
2.95 B USD
2.36 B USD
2.15 B USD
1.92 B USD
228.00 M USD
0.00 USD
Jan 1, 2015
3.22 B USD
2.67 B USD
2.18 B USD
1.93 B USD
248.00 M USD
0.00 USD
Jan 1, 2016
3.62 B USD
3.20 B USD
2.26 B USD
1.99 B USD
261.00 M USD
0.00 USD
Jan 1, 2019
4.21 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
81.00 M USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Boston Scientific Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
country_US excluding Other Net Sales
Int'l
Other Countries
Europe, Middle East and Africa
EMEA
Asia-Pacific
Emerging Markets
APAC
Asia Pacific
Latin America and Canada
Details
Date
United States
country_US excluding Other Net Sales
Int'l
Other Countries
Europe, Middle East and Africa
EMEA
Asia-Pacific
Emerging Markets
APAC
Asia Pacific
Latin America and Canada
Jan 1, 2018
5.54 B USD
0.00 USD
0.00 USD
4.29 B USD
0.00 USD
2.18 B USD
0.00 USD
1.07 B USD
0.00 USD
1.73 B USD
383.00 M USD
Jan 1, 2019
6.10 B USD
0.00 USD
0.00 USD
4.57 B USD
0.00 USD
2.26 B USD
0.00 USD
1.25 B USD
0.00 USD
1.90 B USD
395.00 M USD
Jan 1, 2020
5.51 B USD
0.00 USD
0.00 USD
4.21 B USD
0.00 USD
2.10 B USD
0.00 USD
1.09 B USD
1.78 B USD
0.00 USD
307.00 M USD
Jan 1, 2021
6.90 B USD
0.00 USD
0.00 USD
4.98 B USD
0.00 USD
2.52 B USD
0.00 USD
1.43 B USD
2.07 B USD
0.00 USD
386.00 M USD
Jan 1, 2022
7.63 B USD
7.63 B USD
0.00 USD
5.11 B USD
0.00 USD
2.53 B USD
0.00 USD
1.72 B USD
2.12 B USD
0.00 USD
469.00 M USD
Jan 1, 2023
8.43 B USD
8.43 B USD
0.00 USD
5.82 B USD
0.00 USD
2.86 B USD
0.00 USD
2.31 B USD
2.40 B USD
0.00 USD
560.00 M USD
Jan 1, 2024
10.21 B USD
10.21 B USD
0.00 USD
6.54 B USD
0.00 USD
3.23 B USD
0.00 USD
2.68 B USD
2.69 B USD
0.00 USD
624.00 M USD
Jan 1, 2025
12.86 B USD
0.00 USD
7.21 B USD
0.00 USD
3.45 B USD
0.00 USD
3.08 B USD
2.99 B USD
0.00 USD
0.00 USD
678.00 M USD

Boston Scientific Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Boston Scientific historical P/E ratio, EBIT multiple, and P/S ratio

Boston Scientific annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Boston Scientific shares outstanding

The number of shares of Boston Scientific was 1.5 B in 2025. This indicates how many shares Boston Scientific is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
1.44 B Stocks
Jan 1, 2022
1.44 B Stocks
Jan 1, 2023
1.48 B Stocks
Jan 1, 2024
1.49 B Stocks
Jan 1, 2025
1.50 B Stocks
Jan 1, 2026 (e)
1.50 B Stocks
Jan 1, 2027 (e)
1.50 B Stocks
Jan 1, 2028 (e)
1.50 B Stocks

Boston Scientific stock splits

In Boston Scientific's history, there have been no stock splits.

Current Boston Scientific forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.40 %
Buy
92.50 % (37)
Hold
7.50 % (3)
Sell
0.00 % (0)
12M Price Target
126.99
Last Price
46.73
Currency
USD
12M Return Potential
171.75 %
LTM Return
0 %

Boston Scientific Analyst Rating Actions

DateFirmActionRatingReliability
7/31/2026
Argus Research
Argus Research
DowngradeBuyHold–
7/30/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
7/30/2026
UBS
UBS
MaintainedBuy51
7/30/2026
Truist Securities
Truist Securities
MaintainedBuy–
7/30/2026
TD Cowen
TD Cowen
MaintainedBuy60
7/30/2026
RBC Capital
RBC Capital
MaintainedOutperform52
7/30/2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
7/30/2026
Citigroup
Citigroup
MaintainedBuy48
7/30/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/29/2026
BTIG
BTIG
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Boston Scientific Earnings Calls

2025
2024

Boston Scientific Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/29/20260.84USD-5.42 BUSD-2026 Q2
4/22/20260.80USD-5.22 BUSD-2026 Q1
2/4/20260.79USD-5.33 BUSD-2025 Q4
4/24/20240.52USD-3.70 BUSD-2024 Q1
1/30/20240.52USD-3.63 BUSD-2023 Q4
7/25/20230.49USD-3.47 BUSD-2023 Q2
4/25/20230.45USD-3.22 BUSD-2023 Q1
1/31/20230.48USD-3.29 BUSD-2022 Q4
10/26/20220.45USD-3.18 BUSD-2022 Q3
7/27/20220.43USD-3.26 BUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Boston Scientific stock

71/100
56
Environment
94
Social
63
Governance
E

Environment

20
Scope 1 - Direct Emissions87,567
Scope 2 - Indirect emissions from purchased energy112,861
Scope 3 - Indirect emissions within the value chain2,035,890
Total CO₂ emissions200,429
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49.9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees61
White Management Share77.8
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Boston Scientific shareholder structure

% Name
8.88876%
BLACKROCK, INC.
BLACKROCK, INC.
6.50103%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
5.00508%
FMR LLC
FMR LLC
4.58435%
STATE STREET CORP
STATE STREET CORP
2.24880%
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO
2.24446%
GEODE CAPITAL MANAGEMENT, LLC
GEODE CAPITAL MANAGEMENT, LLC
...

Boston Scientific Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
15.00%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
9.32%
04-2695240
04-2695240
SEC ↗
9.00%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
8.00%
Boston Scientific Corporation
Boston Scientific Corporation
SEC ↗
7.83%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
7.70%
Capital World Investors **
Capital World Investors **
SEC ↗
7.60%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
7.47%
Vanguard Capital Management
Vanguard Capital Management
SEC ↗
7.02%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
6.10%
04-2747644
04-2747644
SEC ↗

Boston Scientific Executives and Management Board

20 members · avg. age 59 · 30 % women

MM

Mr. Michael Mahoney (60)

Chairman of the Board, President, Chief Executive Officer · since 2011

21.42 M USD

Management

JF

Mr. Joseph Fitzgerald (61)

Executive Vice President, Group President - Cardiology

6.34 M USD
AB

Mr. Arthur Butcher (54)

Executive Vice President, Group President, MedSurg and Asia Pacific

5.01 M USD
JM

Mr. Jeffrey Mirviss (59)

Executive Vice President and President - Peripheral Interventions

4.03 M USD
JM

Mr. Jonathan Monson (51)

Chief Financial Officer, Executive Vice President

–
MS

Ms. Miriam O' Sullivan (44)

Chief Human Resources Officer, Senior Vice President

–
JS

Mr. John Sorenson (57)

Executive Vice President - Global Operations

–

Board of Directors

EL

Mr. Edward Ludwig (73)

Lead Independent Director

376,667.00 USD
DW

Mr. David Wichmann (62)

Independent Director

361,667.00 USD
JS

Mr. John Sununu (60)

Independent Director

356,667.00 USD
EZ

Ms. Ellen Zane (73)

Independent Director

356,667.00 USD
YF

Mr. Yoshiaki Fujimori (74)

Independent Director

351,667.00 USD
JM

Dr. Jessica Mega (50)

Independent Director

336,352.00 USD

Boston Scientific Supply Chain

Boston Scientific Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
Lisi
Supplier
0.16
0.12
0.12
0.50
0.78
0.76
1.34
2
Integer Holdings
Supplier
0.67
0.39
0.77
0.54
0.74
0.64
1.09
3
SurModics
Supplier·Customer
0.68
0.44
0.59
0.07
0.81
0.60
2.77
4
Digi International
Supplier
-0.12
0.36
0.68
0.64
0.37
0.55
0.45
5
Benefitfocus
Supplier
0.38
0.14
-0.41
-0.63
-0.10
0.52
—
#Nameβ 1YTrend
1
Aziyo Biologics A
Customer
0.44
0.19
0.13
-0.79
—
—
—
2
Altium Limited
Supplier
0.19
-0.34
—
—
—
—
—
3
Neovasc Inc.
Customer
0.03
0.33
-0.40
-0.59
—
—
—
4
Pluralsight, Inc.
Supplier
-0.34
0.16
0.62
0.56
0.29
—
—
5
Nolato AB (publ)
Supplier
—
—
—
-0.59
-0.81
-0.37
—

Frequently asked questions about Boston Scientific

The main competitors of Boston Scientific Corp in the market include Medtronic, Johnson & Johnson, Abbott Laboratories, and Edwards Lifesciences.

Boston Scientific Corp is a global medical technology company. Its business model revolves around developing innovative medical solutions that enhance patient care and healthcare outcomes. Boston Scientific Corp manufactures and markets a broad range of medical devices used in various specialties, such as cardiology, urology, endoscopy, and neuromodulation. The company's commitment to research and development enables it to introduce advanced technologies and therapies that address unmet clinical needs. Boston Scientific Corp also focuses on collaborations and partnerships to expand its product portfolio, improve access to healthcare, and provide high-quality medical devices to patients worldwide.

Boston Scientific Corp is primarily active in the medical equipment and supplies industry.

Boston Scientific Corp is a renowned medical technology company based in Marlborough, Massachusetts. Established in 1979, it has become a global leader in the development, manufacturing, and marketing of innovative medical devices. With a focus on advancing patient care, Boston Scientific Corp offers a wide range of products for various medical specialties, including interventional cardiology, urology, endoscopy, and neuromodulation. The company's history showcases its commitment to medical breakthroughs and improving the lives of patients worldwide. Boston Scientific Corp's dedication to cutting-edge technology and strategic acquisitions has allowed it to maintain a prominent position in the healthcare industry.

Boston Scientific Corp has achieved significant milestones throughout its history. Some notable achievements include the development of the Taxus Express, a groundbreaking drug-eluting stent that revolutionized the treatment of coronary artery disease. Additionally, the acquisition of Guidant Corporation strengthened Boston Scientific's position in the field of cardiac rhythm management. The company's innovative products, such as the Watchman Left Atrial Appendage Closure device, have provided improved treatment options for patients with atrial fibrillation. Boston Scientific Corp continues to innovate and make advancements in medical technologies, helping to improve patient outcomes worldwide.

Boston Scientific Corp is primarily present in several countries and regions worldwide. The company has a strong global presence, with significant operations in the United States, Europe, Asia-Pacific, Latin America, and the Middle East. Its diverse market reach spans across more than 130 countries, enabling Boston Scientific Corp to provide innovative medical solutions and technologies to a vast range of patients and healthcare professionals worldwide.

Boston Scientific Corp represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patients' lives, the company is committed to developing and delivering innovative medical solutions. Boston Scientific Corp's dedication to collaboration extends to its partnerships with healthcare professionals and institutions, helping to address unmet needs and improve patient outcomes. By prioritizing patient-centric care, the company ensures that its products and services are designed to provide effective and meaningful treatments. Boston Scientific Corp's continued commitment to innovation and collaboration underscores its mission to transform lives through medical advancements in a rapidly evolving healthcare landscape.

Analysts currently set an average price target of 125.50 USD for the Boston Scientific stock (median: 126.99 USD), implying +168.6 % versus the latest price. The consensus is based on 40 analyst ratings.

Boston Scientific Analyst Price Targets 2026

40 analysts currently rate the Boston Scientific stock: 37 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Boston Scientific to generate revenue of 21.60 B USD and earnings per share of 3.33 USD.

Boston Scientific Analyst Price Targets 2026

Converted at the current exchange rate, the Boston Scientific share trades at 41.68 EUR (48.10 USD).

The Boston Scientific share (BSX) is listed on 10 stock exchanges, including: NYSE (BSX), XETRA (BSX.DE), Frankfurt (BSX.F), München (BSX.MU), Düsseldorf (BSX.DU), London (0HOY.L), London (0HOY.L), SIX (Zürich) (BSX.SW).

The Boston Scientific Corporation is a medical technology company that specializes in the manufacturing and development of medical devices. The company was founded in Massachusetts in 1979 and operates globally today. Its business model includes various divisions that focus on different medical specialties. The Cardiac Rhythm Management division of Boston Scientific is involved in the manufacturing of devices for the treatment of heart rhythm disorders. This includes products such as implantable defibrillators, pacemakers, and accessories. The products in this division are of high quality and have an excellent track record in treating patients with severe heart problems. The Interventional Cardiology division of Boston Scientific specializes in the manufacturing of products used in the treatment of heart diseases. This includes balloon catheters, stents, and catheter ablation systems. These products are typically minimally invasive and allow for a quick restoration of normal heart rhythm in patients. The Interventional Radiology division of Boston Scientific is focused on the manufacturing of products for the diagnosis and treatment of vascular diseases. The company produces catheters, stents, and embolization accessories, among other things. Additionally, Boston Scientific is also specialized in the development of products for the treatment of chronic pain. The products in this division include implantable pain therapy systems, neurostimulators, and accessories. These devices can alleviate patients' pain and improve their quality of life. The company is also specialized in the field of urology, including products for the treatment of conditions such as urinary incontinence and benign prostatic hyperplasia. Boston Scientific produces mesh implants and devices aimed at improving bladder control. Furthermore, the company has a division dedicated to gastrointestinal diseases, including products for the treatment of conditions like colorectal cancer and gastrointestinal bleeding. The portfolio includes endoscopes, balloon catheters, and other devices for the treatment of digestive tract disorders. Boston Scientific is committed to providing its customers with the best products. Product development is strongly focused on meeting the needs of patients and doctors. By continually developing new products, the company can expand its market position and maintain its leading position in the medical technology industry.

The expected revenue of Boston Scientific is 21.60 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Boston Scientific is 4.98 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Boston Scientific is currently 14.45. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Boston Scientific stock.

The price-to-sales ratio (P/S) of Boston Scientific is currently 3.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Boston Scientific stock.

The Eulerpool Quality Score for Boston Scientific is 6/10.

The ISIN of Boston Scientific is US1011371077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Boston Scientific is 884113. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Boston Scientific is BSX. The ticker symbol is used to trade Boston Scientific shares on the stock exchange.

Boston Scientific paid dividends every year for the past 0 years.

Boston Scientific is assigned to the 'Health' sector.

The dividends of Boston Scientific are distributed in USD.

All fundamentals and in-depth analysis of Boston Scientific

Our stock analysis for Boston Scientific stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boston Scientific. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Boston Scientific Stock
Boston Scientific Revenue→
Boston Scientific Stock
Boston Scientific Net Income→
Boston Scientific Stock
Boston Scientific P/E→
Boston Scientific Stock
Boston Scientific P/S→
Boston Scientific Stock
Boston Scientific EBIT→
Boston Scientific Stock
Boston Scientific Dividend→
Boston Scientific Stock
Boston Scientific Directors Dealings→
Boston Scientific Stock
Boston Scientific Stocks→
Boston Scientific Stock
Boston Scientific Market capitalization→
Boston Scientific Stock
Boston Scientific Debt→
Boston Scientific Stock
Boston Scientific Liabilities→
Boston Scientific Stock
Boston Scientific Equity→
Boston Scientific Stock
Boston Scientific AAQS→
Boston Scientific Stock
Boston Scientific Employees→
Boston Scientific Stock
Boston Scientific ROE→
Boston Scientific Stock
Boston Scientific ROA→
Boston Scientific Stock
Boston Scientific ROCE→
Boston Scientific Stock
Boston Scientific News→
Boston Scientific Stock
Boston Scientific Analyst Price Targets→

Health Stocks

Botanix PharmaceuticalsBoryungBoule DiagnosticsBorosil ScientificBoundless BioBonus BiogroupBPH EnergyBonraybio CoBPH GlobalBonesupport HoldingBrain ScientificBone BiologicsAll Stocks A–Z →